ADVM vs. STRO, ELEV, CMPX, CHRS, PSTX, XFOR, FENC, IPSC, BDTX, and OPT
Should you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Sutro Biopharma (STRO), Elevation Oncology (ELEV), Compass Therapeutics (CMPX), Coherus BioSciences (CHRS), Poseida Therapeutics (PSTX), X4 Pharmaceuticals (XFOR), Fennec Pharmaceuticals (FENC), Century Therapeutics (IPSC), Black Diamond Therapeutics (BDTX), and Opthea (OPT). These companies are all part of the "biological products, except diagnostic" industry.
Sutro Biopharma (NASDAQ:STRO) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
Adverum Biotechnologies has a net margin of 0.00% compared to Adverum Biotechnologies' net margin of -69.47%. Adverum Biotechnologies' return on equity of -71.42% beat Sutro Biopharma's return on equity.
97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 6.9% of Sutro Biopharma shares are owned by insiders. Comparatively, 5.3% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Adverum Biotechnologies had 3 more articles in the media than Sutro Biopharma. MarketBeat recorded 3 mentions for Adverum Biotechnologies and 0 mentions for Sutro Biopharma. Adverum Biotechnologies' average media sentiment score of 0.72 beat Sutro Biopharma's score of 0.32 indicating that Sutro Biopharma is being referred to more favorably in the media.
Sutro Biopharma has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.
Adverum Biotechnologies received 242 more outperform votes than Sutro Biopharma when rated by MarketBeat users. However, 63.78% of users gave Sutro Biopharma an outperform vote while only 60.81% of users gave Adverum Biotechnologies an outperform vote.
Sutro Biopharma presently has a consensus target price of $12.57, suggesting a potential upside of 267.59%. Adverum Biotechnologies has a consensus target price of $34.67, suggesting a potential upside of 269.19%. Given Sutro Biopharma's higher probable upside, analysts clearly believe Adverum Biotechnologies is more favorable than Sutro Biopharma.
Sutro Biopharma has higher revenue and earnings than Adverum Biotechnologies. Sutro Biopharma is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Summary
Sutro Biopharma beats Adverum Biotechnologies on 11 of the 17 factors compared between the two stocks.
Get Adverum Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adverum Biotechnologies Competitors List
Related Companies and Tools
